LC‒MS/MS was subsequently used to confirm that PRMT5 methylated AKT1 at R391.[27] Based on these findings, in our study, an antibody was also used to determine the methylarginine level of the AKT1‐R391K mutant in colorectal cancer cells when AKT was activated. This evidence concerns the gene PRMT5 and colorectal cancer.